Research programme: cancer stem cell therapeutics - OncoCyte

Drug Profile

Research programme: cancer stem cell therapeutics - OncoCyte

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoCyte Corporation
  • Class Stem cell therapies
  • Mechanism of Action Gene expression stimulants; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 22 May 2015 Preclinical development is ongoing in USA (Parenteral) (OncoCyte, website, May 2015)
  • 26 Jan 2015 OncoCyte Corporation receives patent allowance for applications of stem cells to cancer therapeutics in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top